TheraRadar
Clinical-Stage Companies / LaNova Medicines Limited

LaNova Medicines Limited

Pre-Approval PRO BETA
16
Total Trials
1
Phase 3
13
Phase 2
9
Recruiting
180
Score

Pipeline by Phase

Phase 3
1
Phase 2
13
Phase 1
12

Therapeutic Focus

Advanced Solid Tumor Malignant Tumors Advanced Tumours Locally Advanced or Metastatic GC and GCJ Adenocarcinoma Advanced Solid Tumor Cancer

Clinical Trials (16)

NCT07362186 Phase 3 RECRUITING

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Started: 4/30/2026

NCT07387081 Phase 2 RECRUITING

Phase II Study of LM-24C5

Started: 12/15/2025

NCT06873854 Phase 2 NOT YET RECRUITING

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Started: 3/26/2025

NCT07669415 Phase 2 NOT YET RECRUITING

A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

Started: 6/30/2026

NCT07112222 Phase 1 RECRUITING

A Study of LM-350 in Subjects With Advanced Solid Tumours

Started: 8/28/2025

NCT06682780 Phase 1 RECRUITING

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Started: 9/17/2025

NCT06868199 Phase 1 RECRUITING

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Started: 5/6/2025

NCT06187402 Phase 1 RECRUITING

A Study of LM-24C5 For Advanced Solid Tumors

Started: 12/20/2023

NCT06650566 Phase 1 RECRUITING

Study of LM-299 in Subjects Advanced Malignant Tumors

Started: 10/9/2024

NCT05615974 Phase 1 RECRUITING

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Started: 1/11/2023

NCT05518045 Phase 1 ACTIVE NOT RECRUITING

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

Started: 8/26/2022

NCT05647512 Phase 1 WITHDRAWN

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Started: 1/18/2023

NCT05255484 Phase 1 TERMINATED

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Started: 5/26/2022

NCT04737122 Phase 1 TERMINATED

Study of LM-061 in Subjects in Advanced Tumors

Started: 5/6/2021

NCT04882176 Phase 1 TERMINATED

A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours

Started: 5/20/2021

NCT04735796 Phase 1 TERMINATED

Study of LM-102 in Subjects in Advanced Tumors

Started: 5/27/2021

Drug Candidates

LM-108 in combination with Toripalimab Paclitaxel injection intravenous infusion LM-108 LM-24C5 LM-350 for injection LM-2417 Toripalimab/Tirelizumab LM-168 LM-299 LM101
Activity Status: Active
Last Trial Started: 6/30/2026
Last Trial Ended: 10/6/2023
Trials (12 months): 5
Completed Trials: 0
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.